New medicine for struggle against a malaria

The international group of scientists has declared successful test for monkeys of a new medicine for struggle against a malaria.

Physicians from France, the Netherlands and speak Colombia, that the preparation under name G-25 operates differently, than existing antimalarial means. It quickly kills transferable mosquitoes parasites who amaze erythrocytes.

Tests have shown, that malarial parasites do not develop immunity to new means, and it solves a problem of many medicines existing now.

The malaria transferred through stings of mosquitoes, amazes annually hundred millions people, basically in Africa and Southeast Asia.

While the basic lack of a new preparation is that it can be applied only in the form of injections, but scientists hope, that within two years they can develop the form of a medicine in the form of tablets.
BBC news.

Medicine against illness Parkinson

The British doctors with greater enthusiasm have apprehended preliminary results of experiments on introduction of a new medicine in the damaged areas of a brain of the people, suffering illness Parkinson.
As they said, the new preparation which has received name GDNF, has considerably improved a condition of five patients. One of them again has found ability to feel smells and to laugh.

Results, according to doctors of clinic Frenchay where experiments were spent, have been received more quickly, than it was expected. At the same time they warn, that more large-scale researches are required, and before reception of a high-grade medicine against illness Parkinson will pass as early as years.
http://news.bbc.co.uk

Scientists have found in the sea a medicine against a cancer

It appears, the microbe living in medusoid essence Lissoclinum patella, makes the substance, capable to struggle with fatal disease.

Moreover, researchers approve, that for manufacture of this key making new medicine it will not be necessary to kill in a plenty of sea inhabitants.

The project is spent under aegis of university of state of Utah, the USA, and National fund of a science.

Unique properties belong to microbes under name Prochloron. These microbes make two substances - patellamid A and C which attribute in turn anticancer properties.

" Coral reeves and other sea environments are similar to tropical woods - they are full of substances which bear in itself potential medical properties ", - speaks Erit Shmit, working above the project.

" Unfortunately, reproduction of such substances - hard-hitting a problem. We have solved it by definition of the specific gene responsible for synthesis of these substances, and its introduction in laboratory bacteria ", - explains Shmit.

To the same conclusions about unique properties Prochloron send also scientists from university in Aberdeen together with colleagues from institute of the sea in Australia.

" It is a step forward on a way to a simple and effective method of use of a combination of substance and microbiological technologies for manufacture " medicines from a bottom sea " which in turn does not threaten with destruction of huge quantity of sea organisms ", - Mettju Fletcher from University of the Wales speaks.

Brazil has settled the conflict to pharmacists

Authorities of Brazil not begin to break the patent for a medicine against AIDS after the American pharmaceutical company has agreed to lower cost of the medicine within the nearest six years.

The Brazilian government and company Abbott Laboratories send to the agreement later 10 days of the intense negotiations.

In the past Brazil declared, that will begin release of cheaper version of a preparation "Kaletra", that put strong pressure upon pharmacists so that those have reduced of the price.

On conditions of the agreement, Brazil will get access to the "know-how" of a medicine and will save 250 million dollars the nearest six years.

Now Brazil annually pays companies Abbott Laboratories 107 million dollars for distribution "Kaletra".

In the application of the pharmaceutical company it is spoken, that cost "Kaletra" in Brazil - the lowest in the world outside Africa. Representatives Abbott Laboratories approved, that if the government of Brazil will break the patent legislation the pharmaceutical companies worldwide cannot invest greater means in development of new preparations.

In the past of authority of Brazil already concluded more favourable to the country contracts with other companies after threatened to ignore patents for manufacture of medicines against acquired immunodeficiency syndrome (AIDS).

"Kaletra" is one of the most widespread antiviral the preparations necessary for treatment of a HIV.

For dispute between Brazil and Abbott Laboratories will end with what, steadfastly watched in developing countries where live about 36 million carriers of a human immunodeficiency virus.

By estimations of Ministry of Health of Brazil, in the country with the 183-million population of 600 thousand have a HIV or are sick of AIDS.

As the correspondent BBS Steve Kingston marks from the Dignity the Valve, the decision of the government will be given a hostile reception by active workers of struggle against a HIV.

They actively supported that Brazil has broken the patent on "Kaletra", including, that, by rules, the country has such right. They spoke, that in this case the prices on antiviral medicines all over the world will go downwards.
----------------------------
Wish to have a body of the dream? Practical advice from the trainer will help the beginner!

In the USA the license for a new medicine from AIDS is given out

Management under the control over products and medicines of the USA has licensed for manufacture and sale of a new medicine for a HIV.

It represents a pill containing three medicinal preparations; to accept it it is necessary once a day.

The medicine has been created in common by companies Bristol-Myers-Squibb and Gilead Sciences and refers to Atripla.

It is calculated on those patients it is necessary for them to accept some preparations simultaneously.

It is expected, that the license for distribution Atripla in the Europe will be given out in following to year.

The pill includes a combination of the most widespread preparations which use a AIDS -infected. It became possible owing to cooperation between two companies which make them.

Now patients should accept every day less pills, than several years ago. For them it is very important to adhere to a precise mode of acceptance of medicines, and the new pill just and facilitates this problem.

However, Atripla - a medicine not for all: it will be manages to one person more than in 1000 dollars a month.